Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens
- PMID: 28097528
- DOI: 10.1007/7854_2016_64
Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens
Abstract
Serotonergic hallucinogens induce profound changes in perception and cognition. The characteristic effects of hallucinogens are mediated by 5-HT2A receptor activation. One class of hallucinogens are 2,5-dimethoxy-substituted phenethylamines, such as the so-called 2C-X compounds 2,5-dimethoxy-4-bromophenethylamine (2C-B) and 2,5-dimethoxy-4-iodophenethylamine (2C-I). Addition of an N-benzyl group to phenethylamine hallucinogens produces a marked increase in 5-HT2A-binding affinity and hallucinogenic potency. N-benzylphenethylamines ("NBOMes") such as N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBOMe) show subnanomolar affinity for the 5-HT2A receptor and are reportedly highly potent in humans. Several NBOMEs have been available from online vendors since 2010, resulting in numerous cases of toxicity and multiple fatalities. This chapter reviews the structure-activity relationships, behavioral pharmacology, metabolism, and toxicity of members of the NBOMe hallucinogen class. Based on a review of 51 cases of NBOMe toxicity reported in the literature, it appears that rhabdomyolysis is a relatively common complication of severe NBOMe toxicity, an effect that may be linked to NBOMe-induced seizures, hyperthermia, and vasoconstriction.
Keywords: Head twitch response; Locomotor activity; Psychedelic; Research chemical; Serotonin syndrome.
Similar articles
-
Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.Neuropharmacology. 2014 Feb;77:200-7. doi: 10.1016/j.neuropharm.2013.08.025. Epub 2013 Sep 4. Neuropharmacology. 2014. PMID: 24012658 Free PMC article.
-
Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors.Biochem Pharmacol. 2018 Dec;158:27-34. doi: 10.1016/j.bcp.2018.09.024. Epub 2018 Sep 25. Biochem Pharmacol. 2018. PMID: 30261175 Free PMC article.
-
Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.Neuropharmacology. 2018 Nov;142:240-250. doi: 10.1016/j.neuropharm.2018.02.033. Epub 2018 Mar 1. Neuropharmacology. 2018. PMID: 29501528 Free PMC article.
-
25X-NBOMe compounds - chemistry, pharmacology and toxicology. A comprehensive review.Crit Rev Toxicol. 2023 Jan;53(1):15-33. doi: 10.1080/10408444.2023.2194907. Epub 2023 Apr 28. Crit Rev Toxicol. 2023. PMID: 37115704 Review.
-
NBOMe: new potent hallucinogens--pharmacology, analytical methods, toxicities, fatalities: a review.Eur Rev Med Pharmacol Sci. 2015 Sep;19(17):3270-81. Eur Rev Med Pharmacol Sci. 2015. PMID: 26400534 Review.
Cited by
-
Molecular and Medical Aspects of Psychedelics.Int J Mol Sci. 2023 Dec 23;25(1):241. doi: 10.3390/ijms25010241. Int J Mol Sci. 2023. PMID: 38203411 Free PMC article. Review.
-
Psychedelic-like Activity of Norpsilocin Analogues.ACS Chem Neurosci. 2024 Jan 17;15(2):315-327. doi: 10.1021/acschemneuro.3c00610. Epub 2024 Jan 8. ACS Chem Neurosci. 2024. PMID: 38189238 Free PMC article.
-
Unraveling the In Vitro Toxicity Profile of Psychedelic 2C Phenethylamines and Their N-Benzylphenethylamine (NBOMe) Analogues.Pharmaceuticals (Basel). 2023 Aug 15;16(8):1158. doi: 10.3390/ph16081158. Pharmaceuticals (Basel). 2023. PMID: 37631071 Free PMC article.
-
Acute pharmacological profile of 2C-B-Fly-NBOMe in male Wistar rats-pharmacokinetics, effects on behaviour and thermoregulation.Front Pharmacol. 2023 Mar 9;14:1120419. doi: 10.3389/fphar.2023.1120419. eCollection 2023. Front Pharmacol. 2023. PMID: 36969854 Free PMC article.
-
Analysis of 2,5-dimethoxy-amphetamines and 2,5-dimethoxy-phenethylamines aiming their determination in biological matrices: a review.Forensic Toxicol. 2023 Jan;41(1):1-24. doi: 10.1007/s11419-022-00638-6. Epub 2022 Sep 14. Forensic Toxicol. 2023. PMID: 36652064 Free PMC article. Review.
References
-
- Halberstadt AL (2015) Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res 277:99–120 - PubMed
-
- Quednow BB, Kometer M, Geyer MA, Vollenweider FX (2012) Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 37:630–640 - PubMed
-
- Valle M, Maqueda AE, Rabella M, Rodríguez-Pujadas A, Antonijoan RM, Romero S, Alonso JF, Mañanas MÀ, Barker S, Friedlander P, Feilding A, Riba J (2016) Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur Neuropsychopharmacol 26:1161–1175 - PubMed
-
- Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897–3902 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
